ArticleJournal of contemporary brachytherapy2026
No increased risk for accelerated partial breast irradiation with multicatheter brachytherapy in early-stage invasive lobular carcinoma.
Article in Journal of contemporary brachytherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To analyze the oncological outcomes of adjuvant accelerated partial breast irradiation (APBI) delivered Material and methods: We retrospectively reviewed our institutional database to identify patients with pure or mixed ILC histology, treated with BCS followed by adjuvant APBI by multicatheter brachytherapy. Patients were selected for APBI according to the Groupe Européen de Curiethérapie-European Society for Radiotherapy and Oncology (GEC-ESTRO) recommendations. Ipsilateral breast tumor recurrence (IBTR) and overall survival (OS) were estimated using Kaplan-Meier method. Results: Forty-seven patients with ILC treated between February 2016 and March 2023 were included. Pre-operative breast magnetic resonance imaging (MRI) was performed in 37 patients (78.7%). The median age was 65 years (range, 49-80 years), and the median tumor diameter was 1.1 cm (range, 0-2.5 cm). Forty-four patients (93.6%) met all low-risk criteria; 3 patients (6.4%) were included despite the presence of lymphovascular space invasion (LVSI). Treatment consisted of 32 Gy in 8 fractions for 44 patients (93.6%), and 30.1 Gy in 7 fractions for 3 patients (6.4%). Adjuvant anti-hormonal therapy was given to 42 patients (89.4%). At a median follow-up of 47 months (range, 24-106 months), no IBTR was observed. One non-breast cancer-related death occurred, resulting in a 4-year OS of 97%. Late side effects included mild hyperpigmentation in 2 patients (4.3%) and breast asymmetry in 1 patient (2.1%). Asymptomatic fatty tissue necrosis was detected in 7 patients (14.9%) during follow-up mammography. Conclusions: APBI delivered
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.